Since angiogenesis is linked to immunosuppression in the tumor microenvironment, facilitating the immune escape of tumor cells, antiangiogenic treatment may boost anti-PD-L1 therapy by bolstering vascular alterations [7]. The gene discussed is CD274; the disease is neoplasm.